# RET gene

Type: biological target

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ret-gene
Canonical HTML page: https://gethealthbrief.com/entity/ret-gene

## Recent coverage (1 stories)

### Eli Lilly’s Rs 2.15 lakh cancer pill enters India: Will precision oncology widen the equity gap?
2026-06-26 01:54:12 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Full story: https://gethealthbrief.com/story/tanstrive-india-launch-access-cost

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.